Safety and tolerability of a simplified ramp-up schedule of sonrotoclax in combination with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia: Initial results from a phase 1 global study

ASH 2026 • CLL/SLL • Sonrotoclax, Zanubrutinib • Poster

Matthew S. Davids, MD MMSc

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

This ongoing phase 1/2 study evaluated a simplified outpatient ramp-up and monitoring strategy for investigational sonrotoclax when combined with zanubrutinib in treatment-naive chronic lymphocytic leukemia (TN CLL). As of the data cutoff (April 17, 2026), 56 patients with TN CLL (part 1: n=6; part 2: n=50) completed schedule-limiting toxicity (SLT) observation and were evaluable for the primary endpoint. Forty-four patients (79%) had Binet stage B or C; 27% had high tumor burden, 48% had unmutated immunoglobulin heavy chain variable region (IGHV) gene, 11% had TP53 mutation (variant allele frequency [VAF] ≥10%), and 7% had del(17p). Median absolute lymphocyte count (ALC) was 100.8×10⁹/L (range, 3.8-351.8×10⁹/L). Median study follow-up was 6.3 months (range, 4.7-14.5 months). No cases of laboratory or clinical tumor lysis syndrome occurred. Across all dose levels, 9 patients had transient grade 1 hyperphosphatemia (phosphate levels, 1.52-1.69 mmol/L) that required no medical intervention or sonrotoclax dose modification. No treatment-emergent adverse events (TEAEs) led to discontinuation or dose reduction. The most common any-grade TEAEs were bruising (39%), neutropenia (20%), arthralgia (20%), diarrhea (20%), and headache (20%). Neutropenia (14%) was the only grade ≥3 TEAE reported in ≥5% of patients. No TEAEs led to death.

ClinicalTrials.gov ID: NCT06697184

Population Intervention / Exposure Comparator Outcomes
Patients with treatment-naive chronic lymphocytic leukemia Sonrotoclax plus zanubrutinib N/A
  • Primary endpoint: tumor lysis syndrome incidence (per Howard criteria) during the schedule-limiting toxicity window
  • Secondary endpoints: safety and tolerability, including treatment-emergent adverse events and dose modifications during SLT evaluation

FAQs

This study evaluated a simplified outpatient ramp-up dosing and monitoring strategy for investigational sonrotoclax when combined with zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (TN CLL).

This phase 1/2 study included 2 parts in the TN CLL cohort: part 1 assessed sonrotoclax ramp-up schedule safety in a patient subset before expansion in part 2. Treatment started with 3 cycles (28 days each) of zanubrutinib lead-in (160 mg twice daily or 320 mg once daily). Sonrotoclax was initiated in the outpatient setting on cycle 4 day 1 with weekly ramp-up (2, 5, 20, and 80 mg once daily), reaching the 320 mg once daily target dose after 4 weeks. Combination treatment continued for 12 cycles. Tumor lysis syndrome (TLS) risk was assessed at screening and at the end of zanubrutinib lead-in; TLS prophylaxis included oral hydration and antihyperuricemic agents. TLS monitoring included vital signs and serum chemistry ≤4 hours before and 4-6 hours after the first sonrotoclax dose and each dose increase. The primary endpoint was TLS incidence (per Howard criteria) during the schedule-limiting toxicity (SLT) evaluation window (from initial sonrotoclax dose until 7 days after target dose). Secondary endpoints were safety and tolerability, including treatment-emergent adverse events (TEAEs) and dose modifications during SLT evaluation.

A total of 56 patients with TN CLL completed SLT observation and were evaluable for the primary endpoint (part 1: n=6; part 2: n=50). Median age was 64.5 years (range, 35-80); 71% were male and 82% were White. Forty-four patients (79%) had Binet stage B or C. Twenty-seven percent had high tumor burden (any lymph node ≥10 cm or any lymph node ≥5 cm with ALC ≥25×10⁹/L), 48% had unmutated immunoglobulin heavy chain variable region (IGHV) gene, 11% had TP53 mutation (variant allele frequency [VAF] ≥10%), and 7% had del(17p). Median absolute lymphocyte count (ALC) was 100.8×10⁹/L (range, 3.8-351.8×10⁹/L). Median study follow-up was 6.3 months (range, 4.7-14.5 months).

No laboratory or clinical cases of tumor lysis syndrome occurred among 56 SLT-evaluable patients. Transient grade 1 hyperphosphatemia (phosphate levels, 1.52-1.69 mmol/L) was observed in 9 patients post-dose across all ramp-up levels; none required medical intervention or sonrotoclax dose modification. No other TLS-related laboratory abnormalities (e.g., hyperkalemia or hyperuricemia) were observed within the SLT period.

With median study follow-up of 6.3 months (range, 4.7-14.5 months), no TEAEs led to treatment discontinuation or dose reduction of either study drug. The most common any-grade TEAEs were bruising (39%), neutropenia (20%), arthralgia (20%), diarrhea (20%), and headache (20%). Neutropenia (14%) was the only grade ≥3 TEAE occurring in ≥5% of patients. No TEAEs led to death.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed